// App-Quantinova.ai

PO2637 : 12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1

Researchers

Presenter

  • Saland Jeffrey

Principal Investigators

  • Frishberg Yaacov

  • Hulton Sally

  • Koren Michael

  • Overcash JeffreyScott

  • SELLIER-LECLERC Anne-LaureAll

  • Deschnes Georges

  • Shasha-Lavsky Hadas

  • Hayes WesleyNathan

  • Fuster DanielG

  • Magen Daniella

  • Moochhala ShabbirH

  • Coenen Martin

  • Simkova Eva

  • Garrelfs SanderF

  • Sas DavidJ

  • Meliambro Kristin

  • Ngo Taylor

  • Fujita Kenji

  • Gansner JohnM

  • McGregor Tracy

  • Lieske JohnC

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Emma Kinderziekenhuis Amsterdam UMC Amsterdam Noord-Holland Netherlands

  • Shaare Zedek Medical Center, Jerusalem, Israel

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • 4Jacksonville Center for Clinical Research Jacksonville FL United States

  • eStudySite, San Diego, California, United States

  • Hospices Civils de Lyon, Lyon, France

  • Hôpital Robert-Debré Paris France

  • Galilee Medical center, Naharia, Israel

  • Great Ormond Street Hospital, London, United Kingdom

  • Bern University Hospital and University of Bern, Bern, Switzerland

  • Rambam Health Care Campus, Haifa, Israel

  • The Royal Marsden Hospital, London, United Kingdom

  • University Hospital Bonn, Bonn, Germany

  • Al Jalila Children’s Specialty Hospital, Dubai, United Arab Emirates

  • Mayo Clinic Minnesota Rochester Minnesota United States

  • Alnylam Pharmaceuticals Cambridge Massachusetts United States

Locations

  • United States

  • Netherlands

  • Israel

  • United Kingdom

  • France

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

Disease

  • Primary hyperoxaluria type 1

Biomarkers

  • GC Vitamin D Binding Protein

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved